- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06670651
LinkSymphoKnee (LSK) Total Knee Replacement System Study - Ultra-congruent (UC)
June 5, 2025 updated by: LinkBio Corp.
To collect information about implant performance and patient clinical outcomes in patients undergoing primary total knee arthroplasty with the LinkSymphoKnee total knee replacement system with ultra-congruent tibial bearing surface.
Study Overview
Status
Enrolling by invitation
Intervention / Treatment
Detailed Description
The study will collect outcomes data on up to 600 patients from up to 3 sites using a legally marketed device according to its labeled intended use.
The study will collect:
- KOOS-JR
- Knee Society Score (KSS), 2011
- PROMIS Global Health
- PROMIS Physical Function
- PROMIS Pain Interference
- Surgery Satisfaction
- Forgotten Joint Score
- Radiographic findings
- Revisions.
Radiographic evaluations will be done through postoperative year 2. Other outcomes will be evaluated up to postoperative year 5.
Study Type
Observational
Enrollment (Estimated)
600
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35235
- OrthoAlabama Spine & Sports
-
-
Illinois
-
Libertyville, Illinois, United States, 60048
- Illinois Bone and Joint Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients seeking primary total knee arthroplasty from the participating surgeon investigators
Description
Inclusion Criteria:
- 18 years or older, and skeletally mature; and
- Undergoing a primary TKA for one or both knees using the cemented LinkSymphoKnee knee system as part of the surgeon's standard of care.
- Able to read and understand English (because patient-reported outcome questionnaires are not validated for all potential other languages).
Exclusion Criteria:
- 80 years of age or older,
- Women who are pregnant at the time of surgery,
- History of joint sepsis,
- Bone defect that requires grafting,
- Previous history of bone disease (e.g., severe osteoporosis or osteomalacia) which in the surgeon's opinion is severe enough to compromise device fixation,
- Systemic conditions affecting bone density (e.g., inflammatory arthritis or renal disease) which in the surgeon's opinion are severe enough to compromise device fixation,
- A poorly functioning contralateral total knee replacement or a contralateral revision regardless of function.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Revision rate
Time Frame: 5 years postoperative
|
Evaluates how often patients require additional surgery to remove or replace the knee arthroplasty device components.
|
5 years postoperative
|
|
Knee Injury and Osteoarthritis Outcome Score - Joint Replacement (KOOS-JR) - change from baseline
Time Frame: 1 year postoperative
|
Patient-reported outcome measure (PROM) that assesses knee health based on questions about pain, stiffness, function, and daily activities.
Minimum score = 0. Maximum score = 100.
Higher score means a better outcome.
|
1 year postoperative
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Knee Society Score - change from baseline
Time Frame: postoperative intervals through 5 years
|
A rating scale that measures the outcome of a patient's knee replacement surgery by assessing objective and subjective outcomes, including pain, range of motion, stability, walking distance, and ability to climb stairs, and also patient satisfaction and expectations.
Minimum score = 0. Maximum score = 100.
Higher score means better outcome.
|
postoperative intervals through 5 years
|
|
PROMIS Global Health Score - change from baseline
Time Frame: postoperative intervals through 5 years
|
PROMIS Global Health measures physical function, pain, fatigue, emotional distress, and social health.
The raw score minimum is 7 and maximum is 35.
Higher score means better outcome.
|
postoperative intervals through 5 years
|
|
Surgery Satisfaction Score
Time Frame: 1 and 5 years postoperative
|
Measures a patient's satisfaction with a surgical procedure based on questions about pain control and daily activities.
Minimum score is 0. Maximum score is 10.
Higher score means better outcome.
|
1 and 5 years postoperative
|
|
Forgotten Joint Score
Time Frame: postoperative intervals through 5 years
|
Measures a patient's awareness of their artificial knee joint.
Minimum score is 0. Maximum score is 100.
Higher score means better outcome.
|
postoperative intervals through 5 years
|
|
Knee Society Roentgenographic Evaluation and Scoring System
Time Frame: Through 2 years postoperative
|
Evaluates radiographic signs of device stability.
3 zones are assigned to evaluate the patella component.
5-7 zones are assigned to evaluate the tibia and femur components.
Radiolucencies are evaluated for size, location, and progression over time.
Changes in implant position and/or radiolucencies that are large, continuous, or progressive over time signify possible or impending implant failure.
|
Through 2 years postoperative
|
|
PROMIS Pain Interference Score - change from baseline
Time Frame: postoperative intervals through 5 years
|
The score measures how pain affects a person's life.
The raw score minimum is 6 and maximum is 30.
A lower score means a better outcome.
|
postoperative intervals through 5 years
|
|
PROMIS Physical Function Score - change from baseline
Time Frame: postoperative intervals through 5 years
|
The score measures a person's ability to perform activities.
The raw score minimum is 11 and maximum is 72.5.
A higher score means a better outcome.
|
postoperative intervals through 5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Brian Schwartz, MD, Illinois Bone & Joint Institute
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 21, 2025
Primary Completion (Estimated)
December 1, 2031
Study Completion (Estimated)
December 1, 2031
Study Registration Dates
First Submitted
October 31, 2024
First Submitted That Met QC Criteria
October 31, 2024
First Posted (Actual)
November 1, 2024
Study Record Updates
Last Update Posted (Actual)
June 10, 2025
Last Update Submitted That Met QC Criteria
June 5, 2025
Last Verified
April 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LB24001-LSKUC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
Yuanyuan ZhangRecruitingRheumatoid Arthritis (RA) | Rheumatoid Arthritis-Associated Interstitial Lung Disease | Difficult-to-Treat Rheumatoid ArthritisChina
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
University Hospital, ToulouseCompletedRheumatoId ArthritisFrance
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
-
David Grant U.S. Air Force Medical CenterCompleted
Clinical Trials on total knee arthroplasty device
-
Heekin Orthopedic Research InstituteDePuy Orthopaedics; ConforMIS, Inc.; Stryker OrthopaedicsUnknown
-
Satakunta Central HospitalNot yet recruiting
-
University of PittsburghRecruiting
-
Technische Universität DresdenMathys Ltd BettlachCompletedKnee Osteoarthritis
-
Technische Universität DresdenActive, not recruiting
-
Jesus Moreta SuarezActive, not recruiting
-
Chang Gung Memorial HospitalUnknownComputer-assisted Navigation Versus Conventional Total Knee ReplacementTaiwan
-
Smith & Nephew, Inc.TerminatedDegenerative Arthritis of KneeUnited States, Australia
-
Technische Universität DresdenAesculap AGCompletedOsteoarthritis | Metal Ion LevelsGermany
-
Istituto Ortopedico RizzoliRecruitingKnee Arthroplasty, TotalItaly